Respondents to the GlobalData survey identified barriers to drug pricing and reimbursement as one of the top three challenges facing the pharmaceutical industry. These delays continue to affect biopharmaceutical companies' revenue streams. In the Slovak Republic, insurance companies have so far arbitrarily decided on the payment of medicines for the exception according to Act 363/2011 Coll.[2][1] Coalition MPs submitted a draft law that introduces clear rules and conditions, upon fulfillment of which the insured person will be entitled to reimbursement of an exceptional medicine, medical device or dietetic food.[1] Before payment, the possibility of financing from the new fund for the payment of selected medicines, created by the transformation of the health quality fund, to which insurance companies and pharmaceutical companies will contribute, will be checked.[2][1] Drug registration holders will also contribute to the fund.[2] The draft law takes effect on January 1, 2026, after approval by Parliament.[2] The public defender of rights challenged some provisions on reimbursement of medicines for the exception at the Constitutional Court for unconstitutionality.[1]